.jpg)
58 minutes ago
3
Article content
- Augurex’s SPINEstat® (Anti-14-3-3eta Multiplex for axial spondyloarthritis) test has been selected as a finalist in the ADLM 2026 Disruptive Technology Award, one of laboratory medicine’s most competitive recognition programs.
THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLY
Subscribe now to read the latest news in your city and across Canada.
- Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman, and others.
- Daily content from Financial Times, the world's leading global business publication.
- Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.
- National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.
- Daily puzzles, including the New York Times Crossword.
SUBSCRIBE TO UNLOCK MORE ARTICLES
Subscribe now to read the latest news in your city and across Canada.
- Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman and others.
- Daily content from Financial Times, the world's leading global business publication.
- Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.
- National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.
- Daily puzzles, including the New York Times Crossword.
REGISTER / SIGN IN TO UNLOCK MORE ARTICLES
Create an account or sign in to continue with your reading experience.
- Access articles from across Canada with one account.
- Share your thoughts and join the conversation in the comments.
- Enjoy additional articles per month.
- Get email updates from your favourite authors.
THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK.
Create an account or sign in to continue with your reading experience.
- Access articles from across Canada with one account
- Share your thoughts and join the conversation in the comments
- Enjoy additional articles per month
- Get email updates from your favourite authors
Sign In or Create an Account
or
Article content
- Augurex will present at ADLM 2026 on July 27 in Anaheim, CA, with a dedicated finalist kiosk on the Expo Floor July 28–30.
Article content
Article content
- The recognition underscores Augurex’s leadership in developing biomarker-driven diagnostics that address critical unmet needs across autoimmune and inflammatory diseases.
Article content
Article content
VANCOUVER, British Columbia — Augurex Life Sciences Corp., a leader in the development of autoimmune-based diagnostics, today announced it has been named a finalist in the 2026 Disruptive Technology Award competition presented by the Association for Diagnostics and Laboratory Medicine (ADLM). The company was recognized for SPINEstat® (Anti-14-3-3eta Multiplex), a first-in-class biomarker-based diagnostic test designed to support earlier identification of axial spondyloarthritis (axSpA) and help clinicians differentiate autoimmune-mediated inflammatory disease from mechanical back pain.
Article content
By signing up you consent to receive the above newsletter from Postmedia Network Inc.
Article content
Axial spondyloarthritis is a chronic autoimmune condition that presents as chronic low back pain. Patients with axSpA face diagnostic delays of an average of seven to ten years, and if left untreated, the disease, can lead to severe chronic pain, progressive spinal damage and disability. SPINEstat® was developed to address this critical unmet clinical need by delivering objective biomarker-based evidence to physicians and patients, leading to earlier and more accurate referrals and ultimately, better patient outcomes.
Article content
“Being selected as a finalist for the ADLM Disruptive Technology Award is a meaningful endorsement of the work our team has done in solving one of the most persistent challenges in rheumatology,” said Neil Klompas, President and CEO of Augurex Life Sciences. “The recognition from ADLM affirms that the diagnostic community sees the same urgent need we do, and we look forward to presenting SPINEstat® in Anaheim.”
Article content
The ADLM Disruptive Technology Award is among the most competitive recognition programs in laboratory medicine, evaluating emerging diagnostic technologies based on technical and scientific rigor, clinical relevance, and transformative potential. Augurex’s advancement to the finalist round reflects the high unmet medical need in axSpA as well as the strength of the underlying science, and SPINEstat®’s potential to help transform diagnostic and care pathways.
Article content
As a finalist, Augurex will present SPINEstat® at ADLM 2026 on July 27 in Anaheim, California, where the judges will announce the winner at the close of the session. Augurex will also have a dedicated finalist kiosk on the Expo Floor from July 28–30 during the conference, where attendees can meet with the Augurex team to learn about SPINEstat® and the broader 14-3-3eta biomarker platform.
Article content
Article content
Augurex congratulates all the companies selected as finalists and semi-finalists in this year’s competition.
Article content
To learn more about SPINEstat®, visit: https://augurex.com/axial-spondyloarthritis/ For more information about the ADLM Disruptive Technology Award Announcement, visit: https://meeting.myadlm.org/conference-program/disruptive-technology-award/contestantsAbout Augurex Augurex is a commercial-stage diagnostics company dedicated to the early identification and diagnosis of autoimmune disorders, allowing treatment options to be optimized and personalized for patients around the world. Augurex’s 14-3-3eta blood test, approved as JOINTstat® in Canada and in Great Britain, is an important tool in the diagnosis and management of rheumatoid arthritis. Analyte-specific reagents to detect 14-3-3eta are available for purchase and use by U.S. clinical laboratories as a component of diagnostic tests developed by such laboratories. The Anti-14-3-3eta Multiplex test, approved as SPINEstat® in Canada and Great Britain, expands Augurex’s portfolio of autoimmune diagnostic solutions into axial spondyloarthritis, an autoimmune disease often misdiagnosed as low back pain, which if left untreated, can lead to impaired spinal mobility and fusion of the vertebrae. Learn more about Augurex at www.augurex.com and follow us on Facebook, LinkedIn, and X.
Article content
Article content
Article content
Article content
View source version on businesswire.com:
Article content
Article content
Article content
Contacts
Article content
Media Contact
Article content
Article content
Alanna Kostiw
Article content
Article content
604-637-3280
Article content
Article content
Article content
English (US)